Vicuron Pharmaceuticals is a biopharmaceutical company committed to discovering, developing and commercializing novel antifungal and antibiotic agents with distinct competitive advantages. Its lead products, anidulafungin, a novel antifungal agent, and dalbavancin, a novel antibiotic for the treatment of serious Gram-positive infections, are in the advanced stages of clinical development. The company's versatile research engine integrates industry-leading expertise in functional genomics, automated screening and combinatorial and medicinal chemistry. In addition, Vicuron Pharmaceuticals has extensive research and development collaborations with leading pharmaceutical and anti-infective development companies, such as Pharmacia Corporation, Novartis and Biosearch Italia.
Novartis; Biosearch Italia; Pharmacia